|D013315||Stress, Psychological NIH||0.18|
There is one clinical trial.
COVID19 pandemic and SARS-CoV-2 rapid progression worldwide are already historical landmarks of the 21st century owing to the magnitude of the event and the collective response that populations have adopted to face such threat. This menace has imposed an unprecedented reactivity to promptly deliver answers in various fields and specifically in termes of diagnostic capabilities. The very first tests to be used were based on PCR reactions and on deep nasopharyngeal sampling. But this has shown to be insufficient to prevent contaminations and limit the progression of the disease. This approach requires important infrastructure thus limiting the extent to which it can be delivered. Moreover, nasopharyngeal swab is highly intrusive and therefore is not suitable for repeated testing of asymptomatic patients in surveillance programs. Actual need is based on new tests offering new capabilities both in terms of wide range availability, ease of use and reduced time-to-result duration. Such tests, affordable and that can be performed outside the lab would ultimately relief pressure on healthcare workers and laboratory facilities as well as help test massively wide range of populations thus limiting viral dissemination Such innovating test device has been developped by the start-up "Grapheal" and the present study will ultimately demonstrate the feasibility of COVID-19 diagnostic using this test.
Description: Electric signal obtained in TestNPass Graphene Biosensor for samples collected from known COVID19 positive patients.Measure: Feasibility of TestNPass IVDMD for CoViD19 diagnosis on saliva samples. Time: DAY0 (single visit study, day of COVID19 diagnosis)
Description: Number of failure to obtain data form TestNPass IVDMD in 10 minutes.Measure: TestNPass IVDMD swiftness Time: DAY0 (single visit study, day of COVID19 diagnosis)
Description: Number of "ease of use" score below 22 (included).Measure: TestNPass IVDMD ease of use Time: DAY0 (single visit study, day of COVID19 diagnosis)
Description: TestNPass IVDMD sensibility (in %)Measure: Analytics performance (sensibility) of TestNPass IVDMD Time: DAY0 (single visit study, day of COVID19 diagnosis)
Description: TestNPass IVDMD specificity (in %)Measure: Analytics performance (specificity) of TestNPass IVDMD Time: DAY0 (single visit study, day of COVID19 diagnosis)
Description: TestNPass electric signal amplitude (in %) versus RT-PCR Ct (in AU)Measure: Correlation of TestNPass electric signal intensity with RT-PCR Cycle threshold Time: DAY0 (single visit study, day of COVID19 diagnosis)
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports